After dividing LCNEC subgroups through molecular typing, studies have also found that wild-type RB1 patients who received NSCLC-GEM/TAX treatment had significantly longer OS than those who received SCLC-PE treatment (30). The gene discussed is RB1; the disease is large cell neuroendocrine carcinoma.